Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

176
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
176
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

316
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
316
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

134
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
134
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

228
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
228
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

215
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
215
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preserved Spermatogenesis and Hormonal Function in Men Receiving a Pretomanid Regimen (BPaMZ) for Pulmonary Drug-Resistant Tuberculosis.

Clinical pharmacology and therapeutics·2026
Same author

Routine immunization uptake and timeliness in young children exposed to multidrug-resistant tuberculosis: A secondary analysis of the Tuberculosis Child Multidrug-Resistant Preventive Therapy multi-site randomised controlled trial.

BMC global and public health·2026
Same author

Pharmacokinetics, bactericidal activity and toxicity of short oral regimens for rifampicin-resistant tuberculosis treatment.

Nature communications·2026
Same author

Measuring neighborhood climate and public stigma among veterans with mental illnesses.

BMC psychiatry·2026
Same author

A new anti-inflammatory treatment for bronchiectasis: a viewpoint on optimal dose selection for DPP1 inhibition in clinical practice.

American journal of respiratory and critical care medicine·2026
Same author

Antibiotic dose-response curves can measure antibiotic activity against <i>Mycobacterium abscessus</i> and <i>Mycobacterium peregrinum</i>.

Antimicrobial agents and chemotherapy·2026
Same journal

Evaluation of an application for investments in cataract surgery, Ethiopia.

Bulletin of the World Health Organization·2026
Same journal

An umbrella protocol for the clinical evaluation of diagnostics in infectious disease.

Bulletin of the World Health Organization·2026
Same journal

Fundamental changes in regulation to improve access to biosimilars.

Bulletin of the World Health Organization·2026
Same journal

A public-private partnership for facility-based tuberculosis screening using chest radiographs, Viet Nam.

Bulletin of the World Health Organization·2026
Same journal

Ebola at a critical juncture: preparedness must outpace transmission.

Bulletin of the World Health Organization·2026
Same journal

The need for standardized tracking of investments in digital health.

Bulletin of the World Health Organization·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

Target regimen profiles for tuberculosis treatment.

Christian Lienhardt1, Kelly E Dooley2, Payam Nahid3

  • 1French National Research Institute for Sustainable Development, Montpellier, France.

Bulletin of the World Health Organization
|July 29, 2024
PubMed
Summary
This summary is machine-generated.

The World Health Organization (WHO) updated tuberculosis treatment regimen profiles to guide drug developers. These revised profiles aim for simpler, safer, and more accessible tuberculosis treatments for all patients.

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Related Experiment Videos

Last Updated: Jun 18, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

8.6K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.8K

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pharmacology

Background:

  • Tuberculosis (TB) treatment requires simpler, shorter, safer, and more accessible regimens.
  • The World Health Organization (WHO) established initial TB treatment regimen profiles in 2016.
  • Recent advancements necessitate an update to these critical treatment guidelines.

Purpose of the Study:

  • To revise and update target regimen profiles for tuberculosis treatment.
  • To guide drug developers in creating novel, effective, and accessible TB therapies.
  • To address the needs of patients and programmatic requirements globally.

Main Methods:

  • Updated landscape analysis of current TB treatments.
  • Stakeholder surveys and extensive consultations.
  • Modeling studies on impact and cost-effectiveness of new regimens.

Main Results:

  • Developed revised target regimen profiles for drug-susceptible, drug-resistant, and pan-tuberculosis.
  • Defined minimal and optimal targets for new TB treatments.
  • Included considerations for diagnostics, adherence, treatment strategies, and cost.

Conclusions:

  • Revised WHO target regimen profiles will guide development of quality-assured, affordable TB treatments.
  • These updated profiles aim to meet the needs of populations affected by tuberculosis.
  • The revisions support the creation of more effective and accessible TB therapies worldwide.